Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | THRB | P10828 | 3/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | YWHAG | P61981 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | SLC10A2 | Q12908 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2760934 | 1.00 | MEN1 (0.34) | MEN1MAPTKMT2AKDM4ETHRB | |
| SCHEMBL4872494 | 0.84 | BRD4 (0.37) | MEN1MAPTKMT2AKDM4ECA9 | |
| SCHEMBL4652825 | 0.82 | OPRM1 (0.33) | OPRM1 | |
| SCHEMBL4652845 | 0.80 | NAMPT (0.32) | MEN1MAPTKMT2AKDM4EHSD17B10 | |
| SCHEMBL5732698 | 0.80 | KDM4E (0.33) | KDM4EHSD17B10OPRM1TDP1ALDH1A1 | |
| SCHEMBL4652467 | 0.80 | NAMPT (0.32) | MEN1MAPTKMT2AKDM4EHSD17B10 | |
| SCHEMBL5434554 | 0.80 | NAMPT (0.32) | MEN1MAPTKMT2AKDM4EHSD17B10 | |
| SCHEMBL4652630 | 0.80 | KDM4E (0.33) | KDM4EHSD17B10OPRM1TDP1ALDH1A1 | |
| SCHEMBL4651588 | 0.80 | KDM4E (0.33) | KDM4EHSD17B10OPRM1TDP1ALDH1A1 | |
| SCHEMBL2760981 | 0.78 | CHRNB2 (0.46) | MEN1MAPTKMT2ACHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1436249-B1 | MUSCARINIC AGONISTS | LILLY CO ELI (US) | 2013-11-06 | — | — | EP | disclosed |
| EP-1608617-B1 | MUSCARINIC AGONISTS | LILLY CO ELI (US) | 2013-01-09 | — | — | EP | disclosed |
| EP-1534667-B1 | MUSCARINIC AGONISTS | LILLY CO ELI (US) | 2010-12-15 | — | — | EP | disclosed |
| US-7378447-B2 | Muscarinic agonists | ELI LILLY AND COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-7326731-B2 | Muscarinic agonists | ELI LILLY AND COMPANY (US) | 2008-02-05 | — | — | US | disclosed |
| US-7160922-B2 | Hemihydrate of a selective functional M1 muscarine receptor agonist | ELI LILLY AND COMPANY (US) | 2007-01-09 | — | — | US | disclosed |
| US-20060178438-A1 | Muscarinic agonists | ELI LILLY AND COMPANY (IN) | 2006-08-10 | — | — | US | disclosed |
| US-20060122280-A1 | Muscarinic agonists | ELI LILLY AND COMPANY (US) | 2006-06-08 | — | — | US | disclosed |
| EP-1608617-A1 | MUSCARINIC AGONISTS | ELI LILLY AND COMPANY (US) | 2005-12-28 | — | — | EP | disclosed |
| EP-1534667-A1 | MUSCARINIC AGONISTS | ELI LILLY AND COMPANY (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20040242584-A1 | exemplified by Biphenyl-4-carboxylic acid (R)-(6-(1-((4-fluorobenzyl)methylamino)ethylideneamino) 2(R)-hydroxyindan-1-yl)amide; treating cognitive impairment associated with schizophrenia or Alzheimer's disease | ELI LILLY AND COMPANY | 2004-12-02 | — | — | US | disclosed |
| WO-2004094363-A1 | MUSCARINIC AGONISTS | ELI LILLY AND COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |
| EP-1436249-A2 | MUSCARINIC AGONISTS | ELI LILLY AND COMPANY (US) | 2004-07-14 | — | — | EP | disclosed |
| WO-2004018411-A1 | MUSCARINIC AGONISTS | ELI LILLY AND COMPANY (US) | 2004-03-04 | — | — | WO | disclosed |
| WO-2003027061-A2 | MUSCARINIC AGONISTS | ELI LILLY AND COMPANY (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178438-A1 | Muscarinic agonists | CHRM3, CHRM1, CHRM5 | MEN1 276/4885MAPT 2892/4885KMT2A 2193/4885 |
| US-20040242584-A1 | exemplified by Biphenyl-4-carboxylic acid (R)-(6-(1-((4-fluorobenzyl)methylamino)ethylideneamino) 2(R)-hydroxyindan-1-yl)amide; treating cognitive impairment associated with schizophrenia or Alzheimer's disease | CHRM1, CHRM2, CHRM4 | MEN1 1993/4885MAPT 687/4885KMT2A 917/4885 |
| US-20060122280-A1 | Muscarinic agonists | CHRM3, CHRM4, CHRM5 | MEN1 2272/4885MAPT 2958/4885KMT2A 1268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.